Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).

Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, Heise T, Heinemann L, Roden M, Schloot NC; DIATOR Study Group..

PLoS One. 2012;7(3):e33108. doi: 10.1371/journal.pone.0033108. Epub 2012 Mar 20.

2.

Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.

Martin S, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Kolb H; DIATOR Study Group..

PLoS One. 2011 Mar 11;6(3):e17554. doi: 10.1371/journal.pone.0017554.

3.

[Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus].

Illán Gómez F, Alcaraz Tafalla MS, Pascual Díaz M, Carrillo Alcaraz A.

Med Clin (Barc). 2004 Oct 23;123(14):535-7. Spanish.

PMID:
15535926
4.

The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial).

Kolb H, Lückemeyer K, Heise T, Herder C, Schloot NC, Koenig W, Heinemann L, Martin S; DIATOR Study Group..

PLoS One. 2013 Aug 26;8(8):e72440. doi: 10.1371/journal.pone.0072440. eCollection 2013.

5.

Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.

Ardoin SP, Schanberg LE, Sandborg CI, Barnhart HX, Evans GW, Yow E, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, Levy D, von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy DK, Klein-Gitelman M, Wallace C, Silver RM, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Thompson SD; APPLE investigators..

Ann Rheum Dis. 2014 Mar;73(3):557-66. doi: 10.1136/annrheumdis-2012-202315. Epub 2013 Feb 22.

6.
7.

Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation.

Liu M, Wang F, Wang Y, Jin R.

Cardiovasc Drugs Ther. 2009 Oct;23(5):369-76. doi: 10.1007/s10557-009-6186-3.

PMID:
19636689
8.

Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.

Huptas S, Geiss HC, Otto C, Parhofer KG.

Am J Cardiol. 2006 Jul 1;98(1):66-9. Epub 2006 May 4.

PMID:
16784923
9.

Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus.

Amudha K, Choy AM, Mustafa MR, Lang CC.

Cardiovasc Ther. 2008 Winter;26(4):253-61. doi: 10.1111/j.1755-5922.2008.00064.x.

PMID:
19035876
10.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators..

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
11.

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators..

N Engl J Med. 2005 Jan 6;352(1):29-38.

12.

Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).

Liu PY, Lin LY, Lin HJ, Hsia CH, Hung YR, Yeh HI, Wu TC, Chen JY, Chien KL, Chen JW.

PLoS One. 2013 Oct 1;8(10):e76298. doi: 10.1371/journal.pone.0076298. eCollection 2013. Erratum in: PLoS One. 2014;9(11):e114175.

13.

Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.

Amarenco P, Callahan A 3rd, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KM, Wilson DJ, Zivin JA.

Stroke. 2014 Oct;45(10):2974-82. doi: 10.1161/STROKEAHA.114.005832. Epub 2014 Aug 21.

14.

Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study.

Goyal A, Singh S, Tandon N, Gupta N, Gupta YK.

Can J Diabetes. 2014 Dec;38(6):466-72. doi: 10.1016/j.jcjd.2014.01.006. Epub 2014 Jun 3.

PMID:
24933106
15.

Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.

Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators..

Eur Heart J. 2012 Feb;33(4):486-94. doi: 10.1093/eurheartj/ehr262. Epub 2011 Jul 28.

16.

Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus.

van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C; DALI-Study Group..

Atherosclerosis. 2003 Jan;166(1):129-35.

PMID:
12482559
17.

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.

Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.

J Clin Lipidol. 2013 Jul-Aug;7(4):292-303. doi: 10.1016/j.jacl.2013.03.007. Epub 2013 Apr 3.

PMID:
23890516
18.

Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?

Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S.

Am J Kidney Dis. 2004 Mar;43(3):471-8.

PMID:
14981605
19.

Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.

Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.

Transplant Proc. 2005 Nov;37(9):3808-12.

PMID:
16386546
20.

STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery.

Neilipovitz DT, Bryson GL, Taljaard M.

Can J Anaesth. 2012 Jun;59(6):527-37. doi: 10.1007/s12630-012-9702-z. Epub 2012 Apr 13.

PMID:
22528165

Supplemental Content

Support Center